Fed. Circ. Clears Amgen's Avastin Biosimilar In Notice Fight

Law360 (July 6, 2020, 7:10 PM EDT) -- Genetech's bid to block Amgen from marketing a biosimilar version of its blockbuster cancer drug Avastin fizzled out Monday, with a Federal Circuit panel upholding a Delaware federal judge's decision that Amgen Inc. gave proper notice before going to market.

The precedential opinion shot down Genentech's argument that the Biologics Price Competition and Innovation Act's requirement that biosimilar makers provide 180 days notice before marketing their product was re-triggered when Amgen changed the manufacturing location and label of its biosimilar Mvasi.

Amgen launched Mvasi in July 2019, and it had sales of $121 million last year, according to Amgen's annual report....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!